Karyopharm Therapeutics | KPTI

Karyopharm Therapeutics traded at $3.40 this Friday March 17th, decreasing $0.02 or 0.58 percent since the previous trading session. Looking back, over the last four weeks, Karyopharm Therapeutics lost 6.25 percent. Over the last 12 months, its price fell by 52.65 percent. Looking ahead, we forecast Karyopharm Therapeutics to be priced at 2.90 by the end of this quarter and at 2.64 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
3.40
Daily Change
-0.58%
Yearly
-52.65%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Takeda 4,380.00 99.00 2.31% 21.87%
AbbVie 154.22 -1.08 -0.70% -3.13%
Abbott 96.91 -2.12 -2.14% -20.86%
Amgen 229.79 -4.78 -2.04% -2.73%
Avrobio Inc 1.19 -0.05 -4.03% -25.63%
AstraZeneca 10,790.90 -7.10 -0.07% 13.16%
AstraZeneca 65.61 -0.37 -0.56% 3.76%
BioCryst Pharmaceuticals 8.10 -0.07 -0.86% -50.06%
Bristol-Myers Squibb 66.67 -0.57 -0.85% -6.13%
Enanta Pharmaceuticals 42.09 -1.33 -3.06% -40.33%
GlaxoSmithKline 1,400.80 13.80 1.00% -12.99%
Incyte Corp 73.62 -0.35 -0.47% -2.10%
J&J 152.38 -1.65 -1.07% -12.85%
Karyopharm Therapeutics 3.40 -0.02 -0.58% -52.65%
Eli Lilly 329.18 -0.35 -0.11% 14.44%
MacroGenics 6.65 -0.34 -4.86% -28.57%
Merck & Co 104.10 -3.24 -3.02% 31.59%
Mirati Therapeutics 41.40 -1.47 -3.43% -52.78%
Nektar Therapeutics 0.98 -0.14 -12.49% -82.50%
Novartis 76.24 -0.75 -0.97% -5.62%
Novartis 82.19 -0.59 -0.71% -5.30%
Pfizer 40.10 -0.27 -0.67% -26.44%
Ultragenyx Pharmaceutical 38.53 -1.69 -4.20% -44.78%
Regeneron Pharmaceuticals 747.65 -2.10 -0.28% 9.00%
Roche Holding 260.30 -1.00 -0.38% -28.98%
Sangamo BioSciences 2.01 -0.12 -5.63% -67.42%
TG Therapeutics 14.79 0.13 0.89% 45.71%
Xencor 28.05 -0.28 -0.99% -3.58%

Indexes Price Day Year
USND 11631 -86.76 -0.74% -16.29%
US2000 1726 -45.35 -2.56% -17.27%

Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.